VYNE Therapeutics (VYNE)
(Delayed Data from NSDQ)
$2.50 USD
+0.03 (1.21%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.51 +0.01 (0.40%) 7:00 PM ET
2-Buy of 5 2
D Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
VYNE 2.50 +0.03(1.21%)
Will VYNE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VYNE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VYNE
Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now
What Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock
VYNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
VYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
How Much Upside is Left in VYNE Therapeutics Inc. (VYNE)? Wall Street Analysts Think 626.2%
OptiNose (OPTN) Q2 Earnings and Revenues Top Estimates
Other News for VYNE
12 Health Care Stocks Moving In Friday's After-Market Session
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
Vyne Therapeutics Inc’s New Natural and Human Disruptions Risk – A Cause for Worry?
Vyne Therapeutics files for $250M mixed shelf
VYNE Therapeutics files $250M mixed securities shelf